{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:54:22Z","timestamp":1787741662866,"version":"build-2784847793"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00228-025-03866-y","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T09:58:54Z","timestamp":1749722334000},"page":"1231-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): a narrative review"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Martellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Coluccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-2171","authenticated-orcid":false,"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6158-1045","authenticated-orcid":false,"given":"Giacomo","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"3866_CR1","unstructured":"World Health Organization. Report on the burden of endemic health care-associated infection worldwide. Geneva: World Health Organization; 2011. https:\/\/www.who.int\/publications-detail-redirect\/report-on-the-burden-of-endemic-health-care-associated-infection-worldwide [Accessed January 2025]."},{"issue":"1","key":"3866_CR2","doi-asserted-by":"publisher","first-page":"e0274248","DOI":"10.1371\/journal.pone.0274248","volume":"18","author":"S Raoofi","year":"2023","unstructured":"Raoofi S, Pashazadeh Kan F, Rafiei S, Hosseinipalangi Z, Noorani Mejareh Z, Khani S et al (2023) Global prevalence of nosocomial infection: a systematic review and meta-analysis. PLoS ONE 18(1):e0274248","journal-title":"PLoS ONE"},{"key":"3866_CR3","unstructured":"World Health Organization. Global report on infection prevention and control. Geneva: World Health Organization; 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240051164 [Accessed January 2025]."},{"key":"3866_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"3866_CR5","unstructured":"European Centre for Disease Prevention and Control. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU\/EEA, 2016\u20132020. Stockholm: ECDC; 2022. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/health-burden-infections-antibiotic-resistant-bacteria-2016-2020 [Accessed January 2025]."},{"key":"3866_CR6","unstructured":"European Centre for Disease Prevention and Control. Healthcare-associated infections: surgical site infections. In: ECDC. Annual epidemiological report for 2018\u20132020. Stockholm: ECDC; 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/healthcare-associated-infections-surgical-site-annual-2018-2020 [Accessed January 2025]."},{"key":"3866_CR7","unstructured":"World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017. https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2017.12 [Accessed January 2025]."},{"key":"3866_CR8","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net)-Annual Epidemiological Report 2022. Stockholm: ECDC; 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2022 [Accessed January 2025]."},{"key":"3866_CR9","unstructured":"Surveillance by point prevalence of care-related infections and antibiotic use in acute care hospitals (PPS3) - summary report. Turin: Department of Public Health and Paediatric Sciences, University of Turin. 2023. https:\/\/www.epicentro.iss.it\/sorveglianza-ica\/pdf\/SummaryreportPPS3.pdf [Accessed January 2025]."},{"key":"3866_CR10","unstructured":"Istituto Superiore di Sanit\u00e0. AR-ISS: National Antibiotic-Resistance Surveillance. Data 2022. Rome: Istituto Superiore di Sanit\u00e0; 2023. (ISS Surveillance Reports RIS-4\/2023). https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/ar-iss\/RIS-4_2023.pdf [Accessed January 2025]."},{"key":"3866_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B (2017) Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev 30:409\u2013447","journal-title":"Clin Microbiol Rev"},{"key":"3866_CR12","unstructured":"Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, Falcone M, Giannella M, Grossi P, Pea F, Rossolini GM, Sanguinetti M, Sarti M, Scarparo C, Tumbarello M, Venditti M, Vitale P, Bassettu M, Luzzaro F, Mastroianni CM, Menichetti F, Stefani S, Tinelli M. Diagnosis and management of infections caused by multidrug-resistant bacteria: guidelines of the Italian Society of Infectious and Tropical Diseases (SIMIT), Italian Society of Infectious Therapy (SITA), Italian Group for Antimicrobial Stewardship (GISA), Association of Italian Clinical Microbiologists (AMCLI), Italian Society of Microbiology (SIM). Guideline published in the National Guideline System; 2023. https:\/\/www.iss.it\/documents\/20126\/8331678\/LG+557+Intersocietarie_MDR.pdf\/8b89a49e-6f57-ff09-6e73-c9eb4773aefc?t=1699024001755 [Accessed January 2025]."},{"key":"3866_CR13","unstructured":"Istituto Superiore di Sanit\u00e0. AR-ISS: National Antibiotic-Resistance Surveillance. Data 2021. (ISS Surveillance Reports RIS-1\/2022). Rome: Istituto Superiore di Sanit\u00e0; 2022 https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/ar-iss\/RIS-1_2022.pdf [Accessed January 2025]."},{"key":"3866_CR14","unstructured":"Istituto Superiore di Sanit\u00e0. AR-ISS: National Antibiotic-Resistance Surveillance. 2020 data. (ISS Surveillance Reports RIS-1\/2021). Rome: Istituto Superiore di Sanit\u00e0; 2021. https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/ar-iss\/RIS-1_2021.pdf [Accessed January 2025]."},{"key":"3866_CR15","unstructured":"Istituto Superiore di Sanit\u00e0. AR-ISS: National Antibiotic-Resistance Surveillance. 2019 data. (ISS Surveillance Reports RIS-1\/2020). Rome: Istituto Superiore di Sanit\u00e0; 2020. https:\/\/www.iss.it\/documents\/20126\/0\/RIS-1_2020+(1).pdf\/e4505b37-4ccf-91dc-26e1-57bf05b06492?t=1605538351516 [Accessed January 2025]."},{"key":"3866_CR16","unstructured":"Istituto Superiore di Sanit\u00f2. AR-ISS National Antibiotic-Resistance Surveillance Report No. 1 - Data 2018. Rome: Istituto Superiore di Sanit\u00e0; 2019. https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/ar-iss\/rapporto-1-dati-2018.pdf [Accessed January 2025]."},{"key":"3866_CR17","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/IDR.S228981","volume":"12","author":"M Amin","year":"2019","unstructured":"Amin M, Navidifar T, Shooshtari FS, Rashno M, Savari M, Jahangirmehr F, Arshadi M (2019) Association between biofilm formation, structure, and the expression levels of genes related to biofilm formation and biofilm-specific resistance of Acinetobacter baumannii strains isolated from burn infection in Ahvaz. Iran Infect Drug Resist 12:3867\u20133881","journal-title":"Iran Infect Drug Resist"},{"key":"3866_CR18","doi-asserted-by":"crossref","unstructured":"El-Sayed Ahmed MA, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000\u20132019). Emerging microbes & infections. 2020 Jan 1;9(1):868-85.","DOI":"10.1080\/22221751.2020.1754133"},{"issue":"14","key":"3866_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","volume":"24","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC (2014) Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 24(14):102","journal-title":"BMC Infect Dis"},{"key":"3866_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benfatta YD et al (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18:391\u2013400","journal-title":"Lancet Infect Dis"},{"key":"3866_CR21","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2147\/IDR.S234211","volume":"12","author":"H Shi","year":"2019","unstructured":"Shi H, Lee JS, Park SY, Ko Y, Eom JS (2019) Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist 12:3925\u20133934","journal-title":"Infect Drug Resist"},{"key":"3866_CR22","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","volume":"58","author":"R Sirijatuphat","year":"2014","unstructured":"Sirijatuphat R, Thamlikitkul V (2014) Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 58:5598\u20135601","journal-title":"Antimicrob Agents Chemother"},{"key":"3866_CR23","doi-asserted-by":"crossref","unstructured":"Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator associated pneumonia. Epidemiol Infect. 2013; 141:1214\u201322.","DOI":"10.1017\/S095026881200194X"},{"key":"3866_CR24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ijantimicag.2018.09.008","volume":"52","author":"T Khawcharoenporn","year":"2018","unstructured":"Khawcharoenporn T, Chuncharunee A, Maluangnon C, Taweesakulvashra T, Tiamsak P (2018) Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents 52:828\u2013834","journal-title":"Int J Antimicrob Agents"},{"key":"3866_CR25","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/antibiotics12111593","volume":"12","author":"H Jangid","year":"2023","unstructured":"Jangid H, Kumar D, Kumar G, Kumar R, Mamidi N (2023) Bibliometric examination of global scientific research about carbapenem-resistant Acinetobacter baumannii (CRAb). Antibiotics 12:1593. https:\/\/doi.org\/10.3390\/antibiotics12111593","journal-title":"Antibiotics"},{"key":"3866_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12879-020-05026-2","volume":"20","author":"C Lyu","year":"2020","unstructured":"Lyu C, Zhang Y, Liu X, Wu J, Zhang J (2020) Clinical efficacy and safety of polymyxins based versus nonpolymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. BMC Infect Dis 20:296","journal-title":"BMC Infect Dis"},{"key":"3866_CR27","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America\u00a02023;\u00a0Clinical Infectious Diseases, ciad428,\u00a0https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"issue":"18","key":"3866_CR28","first-page":"30615","volume":"S1473\u20133099","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, Veenhuyzen DV, Echols R, Machida M, Arjona Ferreira JC, Ariyasu M et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis S1473\u20133099(18):30615\u201330617","journal-title":"Lancet Infect Dis"},{"key":"3866_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","volume":"9","author":"JW Wu","year":"2020","unstructured":"Wu JW, Srinivas P (2020) Pogue Cefiderocol: a novel agent for the management of multidrug-resistant gram-negative organisms. Infect Dis Ther 9:17\u201340","journal-title":"Infect Dis Ther"},{"key":"3866_CR30","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion1 (initial authorisation) Fetcroja. 2020 Feb 27. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja [Accessed January 2025]."},{"key":"3866_CR31","unstructured":"AIFA Determination of 10 June 2021 concerning the reclassification of the medicinal product for human use Fetcroja, pursuant to Article 8, paragraph 10, of Law no. 537 of 24 December 1993. (Determination no. DG\/690\/2021) (OJ General Series no. 149 of 24\u201306\u20132021)"},{"key":"3866_CR32","doi-asserted-by":"crossref","unstructured":"Campogiani L, Crea AMA, Minardi ML, Ansaldo L, Coppola L, Compagno M, Vitale P, Spalliera I, Malagnino V, Teti E, D'agostini C, Pennacchiotti C, Abate DN, Celeste MG, Andreoni M, Iannetta M, Sarmati L. Real-life data on cefiderocol efficacy and safety to treat multidrug-resistant Acinetobacter baumannii infections. Open Forum Infect Dis. 2023 Dec 21;10(12): ofad627.","DOI":"10.1093\/ofid\/ofad627"},{"key":"3866_CR33","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C et al (2021) Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in ICU patients. Clin Infect Dis 72:2021\u20132024","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"3866_CR34","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","volume":"76","author":"RK Shields","year":"2023","unstructured":"Shields RK, Paterson DL, Tamma PD (2023) Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis 76(Suppl 2):S179\u2013S193. https:\/\/doi.org\/10.1093\/cid\/ciad094","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3866_CR35","doi-asserted-by":"publisher","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","volume":"66","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, Farcomeni A, Menichetti F (2022) Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 66(5):e0214221. https:\/\/doi.org\/10.1128\/aac.02142-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3866_CR36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/antibiotics12121729","volume":"12","author":"A Karruli","year":"2023","unstructured":"Karruli A, Migliaccio A, Pournaras S, Durante-Mangoni E, Zarrilli R (2023) Cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii. Antibiotics (Basel) 12(12):1729. https:\/\/doi.org\/10.3390\/antibiotics12121729","journal-title":"Antibiotics (Basel)"},{"key":"3866_CR37","doi-asserted-by":"publisher","unstructured":"Pascale R, Pasquini Z, Bartoletti M, Caiazzo L, Fornaro G, Bussini L, Volpato F, Marchionni E, Rinaldi M, Trapani F, Temperoni C. Cefiderocol treatment for carbapenem-resistant Acinetobacterbaumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC-antimicrobial resistance. 2021 Dec 1;3(4):dlab174. https:\/\/doi.org\/10.1093\/jacamr\/dlab174","DOI":"10.1093\/jacamr\/dlab174"},{"issue":"2","key":"3866_CR38","doi-asserted-by":"publisher","first-page":"106882","DOI":"10.1016\/j.ijantimicag.2023.106882","volume":"62","author":"M Kollef","year":"2023","unstructured":"Kollef M, Dupont H, Greenberg DE, Viale P, Echols R, Yamano Y, Nicolau DP (2023) Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence. Int J Antimicrob Agents 62(2):106882. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106882","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"3866_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/antibiotics12040746","volume":"12","author":"G Palermo","year":"2023","unstructured":"Palermo G, Medaglia AA, Pipit\u00f2 L, Rubino R, Costantini M, Accomando S, Giammanco GM, Cascio A (2023) Cefiderocol efficacy in a real-life setting: single-centre retrospective study. Antibiotics (Basel) 12(4):746. https:\/\/doi.org\/10.3390\/antibiotics12040746","journal-title":"Antibiotics (Basel)"},{"key":"3866_CR40","doi-asserted-by":"publisher","unstructured":"Rando E, Cutuli SL, Sangiorgi F, Tanzarella ES, Giovannenze F, De Angelis G, Murri R, Antonelli M, Fantoni M, De Pascale G. Cefiderocol-containing regimens for the treatment of carbapenem-resistant\u00a0A. baumannii\u00a0ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist. 2023 Jul 20;5(4):dlad085. https:\/\/doi.org\/10.1093\/jacamr\/dlad085","DOI":"10.1093\/jacamr\/dlad085"},{"issue":"1","key":"3866_CR41","doi-asserted-by":"publisher","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, Borrazzo C, Quirino A, Lionello R, Serapide F, Garofalo E, Serraino R, Romeo F, Marascio N, Matera G, Longhini F, Trecarichi EM, Torti C (2023) Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents 62(1):106825. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106825","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"3866_CR42","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/antibiotics12061048","volume":"12","author":"L Dalfino","year":"2023","unstructured":"Dalfino L, Stufano M, Bavaro DF, Diella L, Belati A, Stolfa S, Romanelli F, Ronga L, Di Mussi R, Murgolo F, Loconsole D, Chironna M, Mosca A, Montagna MT, Saracino A, Grasso S (2023) Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiotics (Basel) 12(6):1048. https:\/\/doi.org\/10.3390\/antibiotics12061048","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"3866_CR43","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/microorganisms11040984","volume":"11","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Gregori D, Sasset L, Trevenzoli M, Scaglione V, Lo Menzo S, Marinello S, Mengato D, Venturini F, Tiberio I, Navalesi P, Cattelan A (2023) Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic. Microorganisms 11(4):984. https:\/\/doi.org\/10.3390\/microorganisms11040984","journal-title":"Microorganisms"},{"issue":"8","key":"3866_CR44","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","volume":"12","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Papagni R, Belati A, Diella L, De Luca A, Brindicci G, De Gennaro N, Di Gennaro F, Romanelli F, Stolfa S, Ronga L, Mosca A, Pomarico F, Dell\u2019Aera M, Stufano M, Dalfino L, Grasso S, Saracino A (2023) Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study. Infect Dis Ther 12(8):2147\u20132163. https:\/\/doi.org\/10.1007\/s40121-023-00854-6","journal-title":"Infect Dis Ther"},{"issue":"9","key":"3866_CR45","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","volume":"16","author":"F Cal\u00f2","year":"2023","unstructured":"Cal\u00f2 F, Onorato L, De Luca I, Macera M, Monari C, Durante-Mangoni E, Massa A, Gentile I, Di Caprio G, Pagliano P, Numis FG, Iuliano P, Buonomo AR, Leone S, Maggi P, Coppola N (2023) Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: a multicenter observational study. J Infect Public Health 16(9):1485\u20131491. https:\/\/doi.org\/10.1016\/j.jiph.2023.06.009","journal-title":"J Infect Public Health"},{"issue":"3","key":"3866_CR46","doi-asserted-by":"publisher","first-page":"106113","DOI":"10.1016\/j.jinf.2024.01.012","volume":"88","author":"L Onorato","year":"2024","unstructured":"Onorato L, de Luca I, Monari C, Coppola N (2024) Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. J Infect 88(3):106113. https:\/\/doi.org\/10.1016\/j.jinf.2024.01.012","journal-title":"J Infect"},{"issue":"2","key":"3866_CR47","doi-asserted-by":"publisher","first-page":"107047","DOI":"10.1016\/j.ijantimicag.2023.107047","volume":"63","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cosentino F, Giannella M, Viale P, Pea F (2024) Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis. Int J Antimicrob Agents 63(2):107047. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107047","journal-title":"Int J Antimicrob Agents"},{"issue":"372","key":"3866_CR48","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"358","key":"3866_CR49","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"21","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 21(358):j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"issue":"4","key":"3866_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"26","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S (2019) SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 26(4):5. https:\/\/doi.org\/10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"3866_CR51","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [ Apr; 2022 ];GA Wells, B Shea, D O'Connell, et al.\u00a0http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nosgen.pdf\u00a02021"},{"issue":"12","key":"3866_CR52","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1007\/s00210-024-03318-x","volume":"397","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Castagna T, Pantolini B, Campanardi MC, Roperti M, Grotto A, Fattori M, Dal Maso L, Carrara F, Zambarbieri G, Zovi A, Capuozzo M, Langella R (2024) The challenge of antimicrobial resistance (AMR): current status and future prospects. Naunyn Schmiedebergs Arch Pharmacol 397(12):9603\u20139615. https:\/\/doi.org\/10.1007\/s00210-024-03318-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"3866_CR53","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.1007\/s00210-024-03117-4","volume":"397","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Pasquinucci R, Aloisi AC, Polito G, Bagaglini G, Capuozzo M, Zovi A (2024) The use of new antibacterial drugs against infections caused by multidrug-resistant gram-negative bacteria: an Italian real-world evidence study in a Lombardy hospital. Naunyn Schmiedebergs Arch Pharmacol 397(10):8069\u20138075. https:\/\/doi.org\/10.1007\/s00210-024-03117-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"3866_CR54","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/jac\/dkad215","volume":"78","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Belati A, Diella L, Frallonardo L, Guido G, Papagni R, Pellegrino C, Brindicci G, De Gennaro N, Di Gennaro F, Denicol\u00f2 S, Ronga L, Mosca A, Pomarico F, Dell\u2019Aera M, Stufano M, Dalfino L, Grasso S, Saracino A (2023) Loading dose plus continuous\/extended infusion versus intermittent bolus of \u03b2-lactams for the treatment of gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study. J Antimicrob Chemother 78(9):2175\u20132184. https:\/\/doi.org\/10.1093\/jac\/dkad215","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"3866_CR55","doi-asserted-by":"publisher","first-page":"e41414","DOI":"10.7759\/cureus.41414","volume":"15","author":"E Zavaleta","year":"2023","unstructured":"Zavaleta E, Ferrara F, Zovi A, D\u00edaz-Madriz JP, Fallas-Mora A, Serrano-Arias B, Valentino F, Arguedas-Chac\u00f3n S, Langella R, Trama U, Nava E (2023) Antibiotic consumption in primary care in Costa Rica and Italy: a retrospective cross-country analysis. Cureus 15(7):e41414. https:\/\/doi.org\/10.7759\/cureus.41414","journal-title":"Cureus"},{"issue":"2","key":"3866_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/ph17020183","volume":"17","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Pasquinucci R, Capuozzo M, Polito G, Bagaglini G, Vaccaro M, Coluccia A, Langella R, Trama U, Nava E, Zovi A (2024) Comparison and analysis of antibiotic consumption in two Italian hospital settings in relation to the fight of antimicrobial resistance. Pharmaceuticals (Basel) 17(2):183. https:\/\/doi.org\/10.3390\/ph17020183","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"3866_CR57","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/antibiotics13121112","volume":"13","author":"M Capuozzo","year":"2024","unstructured":"Capuozzo M, Zovi A, Langella R, Ottaiano A, Cascella M, Scognamiglio M, Ferrara F (2024) Optimizing antibiotic use: addressing resistance through effective strategies and health policies. Antibiotics (Basel) 13(12):1112. https:\/\/doi.org\/10.3390\/antibiotics13121112","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"3866_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.pharma.2024.01.001","volume":"82","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Capuozzo M, Pasquinucci R, Langella R, Trama U, Nava E, Zovi A (2024) Antibacterial agents and the fight against antibiotic resistance: a real-world evidence analysis of consumption and spending by an Italian healthcare company. Ann Pharm Fr 82(3):545\u2013552. https:\/\/doi.org\/10.1016\/j.pharma.2024.01.001","journal-title":"Ann Pharm Fr"},{"issue":"5","key":"3866_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1701\/4032.40076","volume":"114","author":"F Ferrara","year":"2023","unstructured":"Ferrara F, Zovi A, Nava E, Trama U, Sorrentino S, Vitiello A (2023) Il contrasto dell\u2019antibiotico-resistenza: serve una nuova linea di azione. Recenti Prog Med 114(5):277. https:\/\/doi.org\/10.1701\/4032.40076","journal-title":"Recenti Prog Med"},{"key":"3866_CR60","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI (2024) Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect 30:178\u2013188. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.029","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"3866_CR61","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.1016\/j.ijantimicag.2023.106723","volume":"61","author":"A Karruli","year":"2023","unstructured":"Karruli A, Massa A, Andini R, Marrazzo T, Ruocco G, Zampino R, Durante-Mangoni E (2023) Clinical efficacy and safety of cefiderocol for resistant gram-negative infections: a real-life, single-centre experience. Int J Antimicrob Agents 61(2):106723","journal-title":"Int J Antimicrob Agents"},{"key":"3866_CR62","doi-asserted-by":"crossref","unstructured":"Giannella M, Verardi S, Karas A, Abdel Hadi H, Dupont H, Soriano A, Santerre Henriksen A, Cooper A, Falcone M; ARES Study Group. Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic. Open Forum Infect Dis. 2023 Jul 4;10(7):ofad329.","DOI":"10.1093\/ofid\/ofad329"},{"key":"3866_CR63","doi-asserted-by":"crossref","unstructured":"Shields RK, Dorazio AJ, Tiseo G, Squires KM, Leonildi A, Giordano C, Kline EG, Barnini S, Iovleva A, Griffith MP, Van Tyne D, Doi Y, Falcone M. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146.","DOI":"10.1093\/jacamr\/dlae146"},{"issue":"6","key":"3866_CR64","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","volume":"43","author":"A Oliva","year":"2024","unstructured":"Oliva A, Liguori L, Covino S, Petrucci F, Cogliati-Dezza F, Curtolo A, Savelloni G, Comi M, Sacco F, Ceccarelli G, Viscido A, Alessandri F, Raponi G, Pugliese F, Mastroianni CM, Venditti M (2024) Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. Eur J Clin Microbiol Infect Dis 43(6):1149\u20131160","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3866_CR65","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/cid\/civ717","volume":"61","author":"L Dalfino","year":"2015","unstructured":"Dalfino L, Puntillo F, Ondok MJM, Mosca A, Monno R, Coppolecchia S et al (2015) Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61:1771\u20137. https:\/\/doi.org\/10.1093\/cid\/civ717","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03866-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:24:37Z","timestamp":1757186677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03866-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03866-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which them belong.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}